

**The CAP21 Abstract Program  
CAP21 Annual Meeting  
September 25-28, 2021  
Chicago, Illinois**

**CAP21 Abstract Program Important Dates to Remember:**

<b>January 8, 2021</b>	<b>Abstract submission begins at 9 a.m. Central time</b>
<b>March 8, 2021</b>	<b>Abstract submission closes at 5 p.m. Central time</b>
<b>May 26, 2021</b>	<b>Corresponding authors notified of submission status</b>
<b>August 13, 2021</b>	<b>Top 5 Junior Member Abstract Program winners notified</b>

**Abstract and case study submissions to the CAP21 Abstract Program are currently being accepted. All submissions must be submitted [Here](#).**

The CAP21 Abstract Program is a competitive program sponsored by the College of American Pathologists. The program is designed to promote a broad range of research in pathology. It offers pathologists and research scientists the opportunity to present original research to their peers in a poster presentation format. Editors from the *Archives of Pathology & Laboratory Medicine* will evaluate submissions to this program.

In addition, the CAP21 Abstract Program provides a unique opportunity for residents to enhance research skills, develop writing proficiency, gain practical experience at presenting their findings, and contribute to the literature and advancement of pathology. Accepted abstracts and case studies will be published as a Web-only supplement to the September 2021 issue of the *Archives*. CAP junior members who have their abstracts accepted are eligible for cash awards as part of the Top 5 Junior Member Abstract Program.

**Abstract and case study submissions will be accepted through 5 p.m. Central time Monday, March 8, 2021.**

**CAP21 Abstract Program Evaluation Criteria**

Abstracts will be evaluated on the following criteria:

- Significance of the hypothesis
- Valid conclusion(s)
- Argument clarity
- Presentation quality

Case studies must include novel findings, such as the following:

- A new disease or condition (i.e. not previously reported).
- A distinctive or unusual presentation of a known disease, with one or more well-documented new findings of special clinical relevance (i.e., potentially applicable to diagnosis, therapy, prognosis, etc.) or that serves to provide new insight into the possible pathogenesis of a disease (hypothesis-generating). The new information might be derived from distinctive morphology and/or ancillary testing.

- A known disease with a demonstrated new finding using state-of-the-art techniques (immunohistochemical, molecular, 3-dimensional reconstruction, cytogenetics, etc.) relevant to a clearly stated hypothesis.
- A known disease presenting with a previously undescribed clinically or etiologically relevant association (i.e., a myelodysplastic syndrome associated with a plasma cell dyscrasia, etc.) in order to heighten awareness of a possible link between entities. Such a link might have been described before in one or more individual case reports, and the addition of a case might help solidify a real association.

### **Submission Categories**

Abstracts and case studies may be submitted to the following categories:

#### **Anatomic Pathology**

Autopsy and forensic pathology  
 Bone and soft tissue pathology  
 Breast pathology  
 Cardiovascular pathology  
 Cytopathology  
 Dermatopathology  
 Endocrine pathology  
 Head, neck, and oral pathology  
 Ophthalmic pathology  
 Gastrointestinal and liver pathology  
 Gynecologic and placental pathology  
 Kidney and genitourinary pathology  
 Neuropathology  
 Pulmonary and mediastinal pathology

#### **Clinical Pathology**

Clinical chemistry  
 Clinical immunology  
 Hematopathology  
 Microbiology  
 Molecular pathology  
 Transfusion medicine and coagulation

#### **Practice Management**

Administrative and regulatory affairs  
 Informatics  
 Pathology education  
 Practice management  
 Quality assurance

**Please review the entire submission guidelines using the appropriate link below:**

- [Abstract Submission Guidelines](#)
- [Case Study Submission Guidelines](#)

### **Author Requirements**

Corresponding authors must be available to respond to questions about the content of their submissions from the *Archives* editorial office, especially during the period of April 6 to May 21, 2021. E-mail addresses for corresponding authors must be active and accessible through August 2021.

Corresponding authors will be notified of their submission status on May 26, 2021. Accepted authors will receive specific information regarding poster presentation requirements in their acceptance notification email on May 26.

### **CAP Top 5 Junior Member Abstract Program**

Authors of the top 5 accepted abstracts received from CAP junior members will be named as the Top 5 Junior Member Abstract Program award winners and given cash prizes:

- First place cash award = \$1,500
- Second place cash award = \$1,000
- Third place cash award = \$750
- Fourth and fifth place cash awards are \$500 each.

To be eligible for the CAP21 Top 5 Junior Member Abstract Program awards, a CAP junior member must:

1. Have performed a substantial portion of the research and work involved in the preparation of the abstract;
2. Be listed as either the first or second author;
3. Serve as the corresponding author.

Top 5 Junior Member Abstract Program award winners will be notified by August 13, 2021.

### **Questions**

If you have questions about the abstract program, please e-mail [contactcenter@cap.org](mailto:contactcenter@cap.org) prior to completing your submission. Your questions will be routed to the abstract program coordinator.

**Remember, submissions cannot be changed or resubmitted after the submission deadline.**